title: Is there a path forward for mGlu(2) positive allosteric modulators for the treatment of schizophrenia?
abstract: Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia. The first outcome revealed that Eli Lilly's mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point. The second report showed the mGlu2 positive allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on negative symptoms in patients.
authors: Department of Pharmacology and Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA.
authors: Corey R
authors: CR
authors: Hopkins
mesh_terms: D000494:Allosteric Regulation; D000596:Amino Acids / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D006801:Humans; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D000596:Amino Acids; D014150:Antipsychotic Agents; C534551:LY 2140023; D018094:Receptors, Metabotropic Glutamate; C108822:metabotropic glutamate receptor 2